Comparative study of clinicopathological significance, BIRC7, and STC2 expression between squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder

Neoplasma

Volumn 60, Issue 6, 2013, Pages 698-705

  Yuan, Y ^a   Yang, Z L ^a   Zou, Q ^a   Li, J H ^a   Li, D Q ^a   Liang, L F ^b   Zeng, G X ^c   Chen, S L ^d  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Provincial People s Hospital   (China)

^c Loudi Central Hospital   (China)

^d HUNAN CANCER HOSPITAL   (China)

Author keywords

Adenosquamous carcinomas; BIRC7; Gallbladder cancer; Squamous cell carcinoma; STC2

Indexed keywords

HYPOCALCIN; HYPOCALCIN2; LIVIN; UNCLASSIFIED DRUG; BIRC7 PROTEIN, HUMAN; GLYCOPROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STC2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GALLBLADDER CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR VOLUME; ADENOCARCINOMA; ENZYME IMMUNOASSAY; GALLBLADDER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; GALLBLADDER NEOPLASMS; GLYCOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBITOR OF APOPTOSIS PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84887527477     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2013_089     Document Type: Article

References (40)

1. HSING AW, GAO YT, HAN TQ, RASHID A, SAKODA LC et al. Gallstones and the risk of biliary tract cancer: a populationbased study in China. British J of Cancer. 2007; 97: 1577-82. http://dx.doi.org/10.1038/sj.bjc.6604047
2. OOTANI T, SHIRAI Y, TSUKADA K, MUTO T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer 1992; 69: 2647-52. http://dx.doi.org/10.1002/1097-0142(19920601)69:11<2647::AID-CNCR2820691105>3.0.CO;2-0
3. JAUARAMAN S, JARNAGIN WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010; 39: 331-42. http://dx.doi.org/10.1016/j.gtc.2010.02.006
4. ROA JC, TAPIA O, CAKIR O, BASTURK O, DURSUN N et al. Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol. 2011; 24: 1069-78. http://dx.doi.org/10.1038/modpathol.2011.68
5. REID KM, RAMOS-DE LA MEDINA A, DONOHUE JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg.2007; 11: 671-81. http://dx.doi.org/10.1007/s11605-006-0075-x
6. DE ARETXABALA X, ROA I, BURGOS L, LOSADA H, ROA JC et al. Gallbladder cancer: an analysis of a series of 139 patients with restricted to the subserosal layer. J Gastrointest Surg.2006; 10: 186-92. http://dx.doi.org/10.1016/j.gassur.2005.11.003
7. PARK SB, KIM YH, RHO HL, CHAE GB, HONG SK. Primary carcinosarcoma of the gallbladder. J Korean Surg Soc. 2012; 82: 54-8. http://dx.doi.org/10.4174/jkss.2012.82.1.54
8. MAURYA SK, TEWARI M, MISHRA RR, SHUKLA HS. Genetic aberrations in gallbladder cancer. Surg Oncol. 2012; 21: 37-43. http://dx.doi.org/10.1016/j.suronc.2010.09.003
9. LIU B, HAN M, WEN JK, WANG L. Livin/ML-IAP as a new target cancer treatment. Cancer Lett. 2007; 250: 168-76. http://dx.doi.org/10.1016/j.canlet.2006.09.024
10. WANG L, ZHANG Q, LIU B, HAN M, SHAN B. Challenge and promise: roles for Livin in progression and therapy of cancer. Mol Cancer Ther. 2008; 12: 3661-9. http://dx.doi.org/10.1158/1535-7163.MCT-08-0480
11. AUGELLO C, CARUSO L, MAGGIONI M, DONADON M, MONTORSI M. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer. 2009; 9: 125. http://dx.doi.org/10.1186/1471-2407-9-125
12. LIU HB, KONG CZ, ZENG Y, LIU XK, BI JB et al. Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment. Urol Oncol. 2009; 27: 277-83. http://dx.doi.org/10.1016/j.urolonc.2008.03.015
13. WANG TS, DING QQ, GUO RH, SHEN H, SUN J et al. Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene. Biomed Pharmacother. 2010; 64: 333-8. http://dx.doi.org/10.1016/j.biopha.2009.06.002
14. SUN JG, LIAO RX, ZHANG SX, DUAN YZ, ZHUO WL et al. Role of inhibitor of apoptosis protein Livin in radiation resistance in nonsmall cell lung cancer. Cancer Biother Radiopharm. 2011; 26: 585-92. http://dx.doi.org/10.1089/cbr.2011.0962
15. WAGENER N, CRNKOVIC-MERTENS I, VETTER C, MACHER-GOPPINGER S, BEDKE J et al. Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney. Br J Cancer. 2007; 97: 1271-6. http://dx.doi.org/10.1038/sj.bjc.6604028
16. YE L, SONG X, LI S, YANG D, ZHANG J et al. Livin-α promotes cell proliferation by regulating G1-S cell cycle transition in prostate cancer. Prostate. 2011 Jan 1; 71(1): 42-51. http://dx.doi.org/10.1002/pros.21220
17. WU H, MA Y, ZHU Y, SHEN Y, GU C et al. Expression of BIRC7 protein and mRNA in non-Hodgkin's lymphoma. Leuk Lymphoma. 2006; 47: 1110-6. http://dx.doi.org/10.1080/10428190500472271
18. XIANG Y, YAO H, WANG S, HONG M, HE J et al. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma. Laryngoscope. 2006; 116: 126-30. http://dx.doi.org/10.1097/01.mlg.0000187392.87904.35
19. CHEN L, REN GS, LI F, SUN SQ. Expression of livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma. World J Gastroenterol. 2008; 14: 5749-54. http://dx.doi.org/10.3748/wjg.14.5749
20. KIM DK, ALVARADO CS, ABRAMOWSKY CR, GU L, ZHOU M et al. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr Dev Pathol. 2005; 8: 621-9. http://dx.doi.org/10.1007/s10024-005-4108-3
21. WANG R, LIN F, WANG X, GAO P, DONG K et al. Silencing Livin gene expression to inhibit proliferation and enhance chemosensitivity in tumor cells. Cancer Gene Ther. 2008; 15: 402-12. http://dx.doi.org/10.1038/cgt.2008.16
22. EL ALI Z, GRZYMISŁAWSKI M, MAJEWSKI P, BAUMANNANTCZAK A, KOSOWICZ J. Anti-livin antibodies: novel markers of malignant gastrointestinal cancers. Pol Arch Med Wewn. 2010; 120: 26-9.
23. WANG X, XU J, JU S, NI H, ZHU J et al. Livin gene plays a role in drug resistance of colon cancer cell. Clin Biochem, 2010, 43: 655-660. http://dx.doi.org/10.1016/j.clinbiochem.2010.02.004
24. YEUNG BH, LAW AY, WONG CK. Evolution and roles of stanniocalcin. Mol Cell Endocrinol. 2012; 349: 272-80. http://dx.doi.org/10.1016/j.mce.2011.11.007
25. DIMATTIA GE, VARGHESE R, WAGNER R, WAGNER GF. Molecular cloning and characterization of stanniocalcin-related protein. Mol Cell Endocrinol.1998; 146: 137-40. http://dx.doi.org/10.1016/S0303-7207(98)00163-4
26. VARGHESE R, WONG CK, DEOL H, WAGNER GF. Comparative analysis of mammalian stanniocalcin genes. Endocrinology. 1998; 139: 4714-25. http://dx.doi.org/10.1210/en.139.11.4714
27. YOKOBORI T, MIMORI K, ISHII H, IWATSUKI M, TANAKA F et al. Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann Surg Oncol. 2010; 17: 2601-7. http://dx.doi.org/10.1245/s10434-010-1086-0
28. IETA K, TANAKA F, YOKOBORI T, KITA Y, HARAGUCHI N et al. Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int J Cancer. 2009; 125: 926-31. http://dx.doi.org/10.1002/ijc.24453
29. TAMURA K, FURIHATA M, CHUNG SY, UEMURA M, YOSHIOKA H et al. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Sci. 2009; 100: 914-9. http://dx.doi.org/10.1111/j.1349-7006.2009.01117.x
30. RAULIC S, RAMOS-VALDES Y, DIMATTIA GE. Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro. J Endocrinol. 2008; 197: 517-29. http://dx.doi.org/10.1677/JOE-08-0043
31. KITA Y, MIMORI K, IWATSUKI M, YOKOBORI T, IETA K et al. STC2: a predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma. Ann Surg Oncol. 2011; 18: 261-72. http://dx.doi.org/10.1245/s10434-010-1271-1
32. LAW AY, WONG CK. Stanniocalcin-2 promotes epithelialmesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp Cell Res. 2010; 316: 3425-34. http://dx.doi.org/10.1016/j.yexcr.2010.06.026
33. VIDA KHATAMIANFAR, FATMA VALIYEVA, PAUL S RENNIE, WEI-YANG LU, BURTON B YANG et al. TRIM59, a novel multiple cancer biomarker for immunohistochemical detection of tumorigenesis. BMJ Open. 2012: 2: 1410.
34. SANADA Y, YOSHIDA K, OHARA M, TSUTANI Y. Expression of orotate phosphori-bosyltransferase(OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res. 2007; 13: 105-13. http://dx.doi.org/10.1007/BF02893485
35. XI RC, BIAO WS, GANG ZZ. Significant elevation of survivin and livin expression in human colorectal cancer: inverse correlation between expression and overall survival. Onkologie. 2011; 34: 428-32. http://dx.doi.org/10.1159/000331132
36. DASQUPTA A, ALVARADO CS, XU Z, FINDLEY HW. Expression and functional role of inhibitor of apoptosis protein liviv (BRIRC7). Biochem Biophys Res Commun,2010; 400: 53-59. http://dx.doi.org/10.1016/j.bbrc.2010.08.001
37. WHITE KE, BIBER J, MURER H, ECONS MJ. Chromosomal localization of two human genes involved in phosphate homeostasis: the type IIb sodium-phosphate cotransporter and stanniocalcin-2. Somat Cell Mol Genet. 1998; 24: 357-62. http://dx.doi.org/10.1023/A:1024442524808
38. FUJIWARA Y, SUGITA Y, NAKAMORI S, MIYAMOTO A, SHIOZAKI K et al. Assessment of Stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers. Int J Oncol. 2000; 16: 799-804.
39. ESSEGHIR S, KENNEDY A, SEEDHAR P, NERURKAR A, POULSOM R et al. Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin Cancer Res. 2007; 13: 3164-73. http://dx.doi.org/10.1158/1078-0432.CCR-07-0224
40. JOENSUU K, HEIKKILA P, ANDERSSON LC. Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer. Cancer Lett. 2008; 265: 76-83. http://dx.doi.org/10.1016/j.canlet.2008.02.022